Tel: 020-67320420 About Us Contact Us

Global CAR-T Cell Therapy Market

Global CAR-T Cell Therapy Market, By Product Type, By Target Antigen Type, By Disease/Indication Type, By Manufacturing Method, By Technology/Vector Type, By Therapy Type, By End User and By Region Forecast to 2032

Global CAR-T Cell Therapy Market, By Product Type, By Target Antigen Type, By Disease/Indication Type, By Manufacturing Method, By Technology/Vector Type, By Therapy Type, By End User and By Region Forecast to 2032

Category: Healthcare Published Date : SEP-02 ID: AG01139 Format: PDF Pages: 298

Talk to Analyst Request for Customization Request for Free Sample

Market Synopsis

The global CAR-T Cell Therapy market size was USD 5,395.26 million in 2024 and is expected to reach USD 72,597.71 million during a forecast period from 2025-2032 at a CAGR of 38.41%. The global CAR T-cell therapy market is experiencing strong momentum, supported by the growing burden of cancer, high response rates in difficult-to-treat cases, and broader regulatory approvals. The therapy is gaining recognition as a breakthrough in personalized medicine, with ongoing innovations in gene editing and manufacturing expanding its applications into solid tumors and even autoimmune diseases. North America currently dominates the market due to advanced infrastructure and early adoption, while Asia-Pacific is emerging as the fastest-growing region with significant investments in local clinical programs. Although high treatment costs and complex manufacturing remain key challenges, advancements in automation and scalable production technologies are helping address these barriers. Together, these trends position CAR T-cell therapy as a cornerstone of future cancer treatment and long-term market growth.

Global CAR-T Cell Therapy Market (USD Million)

Global CAR-T Cell Therapy Market

  Global CAR T Cell Therapy Market by Product Type Insights:

Yescarta and Kymriah segments accounted for 54.54% of share in 2025 in Global CAR-T Cell Therapy market.

The Yescarta (Axicabtagene Ciloleucel) and Kymriah (Tisagenlecleucel) segments together accounted for the largest share of the global CAR T-cell therapy market in 2025, representing 54.54% of total revenues. Yescarta is projected to grow at a CAGR of 38.54%, while Kymriah is expected to expand at 39.02% during 2025–2032, with their combined revenues anticipated to reach USD 40,568.66 million by 2032. Their dominance stems from proven clinical outcomes, expanded regulatory approvals, and strong commercialization networks by Gilead Sciences and Novartis, ensuring global accessibility and sustained adoption. Meanwhile, Breyanzi (Lisocabtagene Maraleucel) has gained traction with its differentiated safety profile and flexible dosing strategy, making it a preferred alternative in relapsed and refractory lymphoma. Backed by Bristol Myers Squibb, it continues to grow through label expansions and global clinical trial activity.

Abecma (Idecabtagene Vicleucel) plays a vital role in multiple myeloma treatment, particularly for patients who have exhausted prior therapies. Its rapid adoption is supported by robust real-world evidence of durable responses, while Bristol Myers Squibb and 2seventy bio are investing heavily in expanding production to meet rising demand across the U.S. and Europe. At the same time, Carvykti (Ciltacabtagene Autoleucel / Cilta-cel) is emerging as the fastest-growing therapy, with efficacy rates of nearly 98% making it the preferred option in multiple myeloma. Janssen Biotech and Legend Biotech are scaling up global manufacturing capacity and patient access programs to accelerate uptake, especially across Asia and Europe, driving significant revenue growth over the forecast horizon.

Tecartus (Brexucabtagene Autoleucel), developed by Kite Pharma, has established a strong foothold in mantle cell lymphoma (MCL) and acute lymphoblastic leukemia (ALL), supported by favourable reimbursement policies and regional approvals. Its clinical value and ongoing trial programs position it for steady expansion into broader hematologic malignancy indications. Together, these six therapies illustrate how the CAR T-cell therapy market is diversifying, with Yescarta and Kymriah driving scale, Carvykti advancing on unmatched efficacy, and others like Breyanzi, Abecma, and Tecartus fulfilling critical gaps in hematologic oncology. This balance of innovation and competition underscores the dynamic growth trajectory of the global market.

Global CAR-T Cell Therapy Market, By Product Type (USD Million)

Global CAR-T Cell Therapy Market By Product Type

Global CAR T Cell Therapy Market by Target Antigen Type Insights:

CD19 (Cluster of Differentiation 19) segment accounted for 48.58% of share in 2025 in Global CAR-T Cell Therapy market.

The global CAR T-cell therapy market, when segmented by target antigen type, includes CD19, BCMA, CD22, GD2, HER2, GPC3, and Others (such as EGFRvIII, CD7, CD123, and mesothelin). Among these, the CD19 (Cluster of Differentiation 19) segment held the largest revenue share of 48.58% in 2025 and is projected to register a CAGR of 38.66% during the forecast period, reaching USD 36,102.21 million by 2032. CD19’s dominance is driven by its proven clinical effectiveness in treating B-cell malignancies like acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Widely commercialized therapies including Yescarta, Kymriah, and Breyanzi target this antigen, ensuring strong physician confidence, broad regulatory support, and global accessibility—factors that firmly position CD19 as the foundation of the CAR T-cell therapy landscape.

BCMA (B-cell Maturation Antigen) has emerged as the next most influential target, demonstrating remarkable efficacy in multiple myeloma. Flagship therapies such as Abecma and Carvykti have accelerated market momentum, with Carvykti reporting near 98% response rates, reinforcing BCMA’s rapid growth trajectory. At the same time, CD22 and GD2 are advancing through clinical studies, showing promise in both hematological and solid tumor indications. HER2 and GPC3 are generating attention for their potential in breast and liver cancers, although their commercial maturity is still in early phases. The “Others” category—covering targets like EGFRvIII, CD7, CD123, and mesothelin—represents the frontier of innovation, with next-generation CAR T therapies aiming to address hard-to-treat cancers and reduce relapse rates in high-risk patient populations.

Global CAR-T Cell Therapy Market, By Target Antigen Type (USD Million)

Global CAR-T Cell Therapy Market By Target Antigen Type

Global CAR T Cell Therapy Market by Disease/Indication Type Insights:

Hematologic Malignancies (Blood Cancers) segment accounted for 65.63% of share in 2025 in Global CAR-T Cell Therapy market.

The global CAR T-cell therapy market by disease/indication type is segmented into hematologic malignancies, solid tumors, and other diseases. Hematologic malignancies led with a 65.63% share in 2025 and are projected to grow at a CAGR of 38.69%, reaching USD 48,318.48 million by 2032. Their dominance is supported by the proven success of CAR T therapies in lymphoma, leukemia, and multiple myeloma. Within lymphoma, subtypes such as Diffuse Large B-cell Lymphoma (DLBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Mantle Cell Lymphoma (MCL), and Follicular Lymphoma (FL) respond strongly to CD19-targeted therapies like Yescarta, Kymriah, Breyanzi, and Tecartus. In leukemia, Acute Lymphoblastic Leukemia (ALL) achieved breakthroughs with Kymriah’s pediatric approval, while Chronic Lymphocytic Leukemia (CLL) is advancing in trials. Multiple myeloma, fueled by BCMA-directed therapies such as Abecma and Carvykti, is growing rapidly due to outstanding efficacy and durable responses.

In contrast, solid tumors remain an emerging frontier, limited by barriers like tumor microenvironment resistance and antigen heterogeneity. Despite these challenges, research momentum is rising across glioblastoma, pancreatic cancer, ovarian cancer, and lung cancer, with exploratory efforts in breast cancer, melanoma, prostate cancer, and colorectal cancer. Novel strategies such as dual-target CARs, localized delivery methods, and armored CAR constructs are showing promise, gradually improving clinical outcomes and signaling long-term growth potential in these indications.

The Other Diseases segment highlights CAR T’s expansion beyond oncology, with encouraging results in autoimmune disorders such as lupus and rheumatoid arthritis, and exploratory studies in infectious diseases including HIV and virus-associated cancers. Together, these advances illustrate a market where hematologic malignancies remain the growth engine, while solid tumors and other diseases represent high-reward opportunities. To sustain leadership, companies like Novartis, Gilead, Bristol Myers Squibb, and Janssen are consolidating their hematologic portfolios while strategically investing in next-generation pipelines, manufacturing scale-up, and patient access programs to drive the next wave of CAR T-cell therapy expansion.

Global CAR-T Cell Therapy Market, By Disease/Indication Type (USD Million)

Global CAR-T Cell Therapy Market By Disease/Indication Type

Global CAR T Cell Therapy Market by Manufacturing Method Type Insights:

Centralized Manufacturing segment accounted for 74.51% of share in 2025 in Global CAR-T Cell Therapy market.

Based on manufacturing method, the global CAR T-cell therapy market is segmented into Point-of-Care Manufacturing, Centralized Manufacturing, In-vivo CAR T Therapy Manufacturing, and Off-the-Shelf/Ready-to-Use Therapies. Among these, Centralized Manufacturing holds the largest share of 74.51% in 2025, projected to expand at a CAGR of 38.69% and reach USD 54,852.84 million by 2032. This dominance is driven by its established infrastructure, strict quality standards, and ability to deliver consistent therapies across global markets. Centralized facilities provide specialized expertise, regulatory compliance, and economies of scale, allowing leading companies to ensure reproducibility and reliability while meeting rising demand. Strong supply chains, cryopreservation advancements, and scalable production also make this model the backbone of current CAR T commercialization.

Meanwhile, other manufacturing approaches are emerging to address limitations of centralized models. Point-of-Care Manufacturing aims to reduce vein-to-vein time by producing therapies closer to patients, while In-vivo CAR T therapy manufacturing explores direct engineering of T-cells inside the body to streamline processes. Similarly, Off-the-Shelf or Ready-to-Use therapies, built on allogeneic cell platforms, promise scalable and more affordable options without the need for patient-specific cells. Though these approaches are still developing, they highlight a strong shift toward accessibility and cost-effectiveness. However, in the near term, Centralized Manufacturing will continue to dominate, offering the most reliable path to global scalability and fueling the rapid growth of the CAR T-cell therapy market.

Global CAR-T Cell Therapy MARKET, By manufacturing method Type (USD Million)

Global CAR T Cell Therapy Market by Manufacturing Method

Global CAR T Cell Therapy Market by Manufacturing Method Type Insights:

Viral Vectors segment accounted for 72.34% of share in 2025 in Global CAR-T Cell Therapy market.

Based on technology/vector type, the global CAR T-cell therapy market is segmented into Viral Vectors, Non-Viral Vectors, Armored CAR T-Cells, Safety Switch-Equipped CAR T-Cells, and Dual & Multiple Antigen Targeting CAR T-Cells. Among these, Viral Vectors accounted for the largest revenue share of 73.21% in 2025 and are expected to grow at a CAGR of 38.69%, reaching USD 53,899.13 million by 2032. Their dominance is driven by the proven efficiency of lentiviral and retroviral vectors in enabling stable gene integration and robust expression of CAR constructs. Viral vector platforms are widely adopted due to their ability to generate long-lasting therapeutic effects, which is critical for sustained remission in cancer patients. This reliability has established viral vectors as the cornerstone of current CAR T-cell development and commercialization.

The growth of this segment is further fueled by continuous advancements in viral engineering that enhance safety, scalability, and production efficiency. Centralized manufacturing facilities equipped for viral vector production support large-scale clinical and commercial supply, ensuring global accessibility. While non-viral alternatives such as CRISPR/Cas9, transposons, and mRNA electroporation are gaining traction for their potential cost-effectiveness and reduced manufacturing complexity, they remain in earlier stages of adoption. At the same time, next-generation approaches like Armored CAR T-cells, Safety Switch-equipped therapies, and multi-antigen targeting platforms are shaping the future landscape by improving safety, durability, and efficacy. However, in the near-to-midterm, viral vectors are expected to retain their dominance as the most reliable and commercially viable backbone of CAR T-cell therapy manufacturing.

Global CAR-T Cell Therapy Market, By Technology/Vector Type (USD Million)

Global CAR-T Cell Therapy MARKET, By Technology

Global CAR T Cell Therapy Market by Therapy Type Insights:

Autologous segment accounted for 88.13% of share in 2025 in Global CAR-T Cell Therapy market.

Based on therapy type, the global CAR T-cell therapy market is segmented into Autologous and Allogeneic CAR T-cell therapies. Among these, the Autologous segment accounted for the largest revenue share of 88.13% in 2025 and is expected to register a CAGR of 38.76% during the forecast period, with revenues projected to reach USD 65,108.79 million. The dominance of this segment is attributed to its highly personalized approach, where T-cells are collected directly from the patient, genetically modified to express chimeric antigen receptors (CARs), and reinfused to specifically target cancer cells. This individualized method significantly reduces the risk of immune rejection and graft-versus-host disease, ensuring a higher safety profile and better therapeutic outcomes. Autologous CAR T therapies are particularly effective for patients with refractory or relapsed cancers, where conventional treatments have failed, making them the preferred choice in clinical practice.

The segment’s growth is further supported by its strong clinical adoption, as leading CAR T therapies currently approved and marketed globally are predominantly autologous in nature. These therapies have demonstrated remarkable remission rates in hematologic malignancies such as leukemia and lymphoma, building a strong foundation of trust among healthcare providers and patients. Moreover, advancements in manufacturing technologies are gradually reducing production times and improving scalability, which has historically been a challenge for personalized autologous treatments. At the same time, expanding clinical trials are exploring its application across solid tumors, broadening its therapeutic reach. While Allogeneic therapies promise off-the-shelf availability and faster turnaround times, Autologous CAR T-cell therapy continues to lead the market due to its established efficacy, safety, and regulatory approvals. This ensures that autologous approaches will remain the driving force behind CAR T-cell therapy growth in the coming years.

Global CAR-T Cell Therapy Market, By Therapy Type (USD Million)

Global CAR-T Cell Therapy Market, By Therapy Type

Global CAR T Cell Therapy Market by End User Insights:

Hospitals segment accounted for 49.46% of share in 2025 in Global CAR-T Cell Therapy market.

Based on end user segment, the global CAR T-cell therapy market is segmented into Hospitals, Cancer Treatment Centers, and Others (Academic & Research Institutes, Specialty Clinics). Hospitals accounted for the largest share of 49.46% in 2025 and are projected to grow at a CAGR of 38.69%, reaching USD 36,851.69 million. This leadership is driven by their advanced infrastructure, specialized oncology units, and capacity to manage complex procedures such as T-cell collection, modification, reinfusion, and post-treatment care. Hospitals also remain the most reliable settings for handling side effects like cytokine release syndrome and neurotoxicity, ensuring patient safety and treatment success.

The segment further benefits from strong collaborations with biopharma companies and research institutes, giving patients access to the latest therapies and clinical trials. Rising investments in hospital-based cell therapy units and the growing global cancer burden continue to expand demand. While cancer treatment centers and academic institutions contribute to innovation and specialty care, hospitals dominate due to their scale, comprehensive patient support, and integrated services, making them the cornerstone of CAR T-cell therapy adoption worldwide.

Global CAR-T Cell Therapy Market, By End User (USD Million)

Global CAR-T Cell Therapy Market, By End User

Global CAR T Cell Therapy Market by Region Insights:

North America segment accounted for 48.62% of share in 2025 in Global CAR-T Cell Therapy market.

Based on region, the global CAR T-cell therapy market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America held the largest revenue share of 48.63% in 2025 and is projected to grow at a CAGR of 38.52%, reaching USD 35,665.86 million. The region’s leadership is primarily attributed to its strong biotechnology ecosystem, presence of leading CAR T developers, and advanced healthcare infrastructure. The United States, in particular, dominates the market with FDA approvals, well-established clinical trial networks, and access to cutting-edge cell processing facilities. High cancer incidence rates, favorable reimbursement frameworks, and strong patient awareness have further accelerated adoption across hospitals and specialized cancer centers.

Additionally, North America benefits from significant R&D investments, collaborations between pharma companies and academic institutions, and government support for novel oncology therapies. The region is also witnessing rapid expansion of commercial manufacturing sites and streamlined regulatory pathways, which shorten therapy availability timelines. Robust insurance coverage and the growing integration of CAR T-cell therapies into clinical practice guidelines have reinforced patient access. While other regions such as Europe and Asia Pacific are advancing with supportive regulations and rising adoption, North America remains at the forefront due to its innovation-driven ecosystem, strong commercial presence, and comprehensive healthcare support, positioning it as the global leader in CAR T-cell therapy throughout the forecast period.

Global CAR-T Cell Therapy Market, By Region (USD Million)

Global CAR-T Cell Therapy Market, By Region

Major Companies and Competitive Landscape 

The global CAR T-cell therapy market is fragmented, with large and emerging players accounting for the majority of market revenue. Major companies are adopting strategies such as mergers and acquisitions, strategic collaborations, licensing agreements, and product pipeline expansions. These efforts are focused on enhancing therapeutic efficacy, improving safety, scaling manufacturing, and broadening clinical applications to meet growing patient demand. Some of the leading companies profiled in the global CAR T-cell therapy market report include:

    • Bluebird Bio
    • Celgene Corporation
    • Gilead Sciences
    • Cellectis
    • Servier Laboratories
    • Pfizer Inc.
    • Merck
    • Amgen
    • Intellia Therapeutics
    • Novartis
    • Caribou Biosciences
    • Celyad
    • Bellicum Pharmaceuticals, Inc.
    • Noile-Immune Biotech
    • Nanjing Legend Biotechnology Co., Ltd.
    • Johnson & Johnson
    • Sangamo Therapeutics, Inc.
    • Autolus Therapeutics
    • Poseida Therapeutics
    • Allogene Therapeutics
    • BioNTech
    • Cartesian Therapeutics
    • Roche
    • AstraZeneca
    • HaemaLogiX

Scope of Research

Report Details Outcome
Market size in 2024 USD 5,395.26 Million
CAGR (2024–2032) 38.41%
Revenue forecast to 2033 USD 72,597.71 Million
Base year for estimation 2024
Historical data 2019–2023
Forecast period 2025–2032
Quantitative units Revenue in USD Million, and CAGR in % from 2025 to 2032
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered By Product Type, By Target Antigen Type, By Disease/Indication Type, By Manufacturing Method, By Technology/Vector Type, By Therapy Type, By End User and By Region
Regional scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Country scope U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Benelux, Russia, Finland, Sweden, Rest of Europe, China, India, Japan, South Korea, Indonesia, Thailand, Vietnam, Australia, New Zealand Rest of APAC, Brazil, Rest of LATAM, Saudi Arabia, UAE, South Africa, Turkey, Rest of MEA
Key companies profiled Bluebird Bio, Celgene Corporation, Gilead Sciences, Cellectis, Servier Laboratories, Pfizer Inc., Merck, Amgen, Intellia Therapeutics, Novartis, Caribou Biosciences, Celyad, Bellicum Pharmaceuticals, Inc., Noile-Immune Biotech, Nanjing Legend Biotechnology Co., Ltd., Johnson & Johnson, Sangamo Therapeutics, Inc., Autolus Therapeutics, Poseida Therapeutics, Allogene Therapeutics, BioNTech, Cartesian Therapeutics, Roche, AstraZeneca, HaemaLogiX.
Customization scope 10 hours of free customization and expert consultation

Follow us on: Facebook, Twitter, Instagram and LinkedIn.









Chapter 1. Introduction

1.1. Market Definition

1.2. Objectives of the study

1.3. Overview of global CAR-T cell therapy market

1.4. Currency and pricing

1.5. Limitation

1.6. Markets covered

1.7. Research Scope

Chapter 2. Research Methodology

   2.1. Research Sources

       2.1.1.Primary

       2.1.2.Secondary

       2.1.3.Paid Sources

2.2. Years considered for the study

2.3. Assumptions

       2.3.1.Market value

       2.3.2.Market volume

       2.3.3.Exchange rate

       2.3.4.Price

       2.3.5.Economic & political stability

Chapter 3. Executive Summary

   3.1. Summary Snapshot, 2025-2032

Chapter 4. Key Insights

4.1. Production consumption analysis

4.2. Strategic partnerships & alliances

4.3. Joint ventures

4.4. Acquisition of local players

4.5. Contract manufacturing

4.6. Digital & e-commerce sales channels

4.7. Compliance with standards

4.8. Value chain analysis

4.9. Raw material sourcing

4.10.Formulation & manufacturing

4.11.Distribution & retail

4.12.Import-export analysis4.13.Brand comparative analysis

4.14.Technological advancements

4.15.Porter’s five force

   4.15.1.Threat of new entrants

       4.15.1.1.Capital requirment

       4.15.1.2.Product knowledge

       4.15.1.3.Technical knowledge

       4.15.1.4.Customer relation

       4.15.1.5.Access to appliation and technology

   4.15.2.Threat of substitutes

       4.15.2.1.Cost

       4.15.2.2.Performance

       4.15.2.3.Availability

       4.15.2.4.Technical knowledge

       4.15.2.5.Durability

   4.15.3.Bargainning power of buyers

       4.15.3.1.Numbers of buyers relative to suppliers

       4.15.3.2.Product differentiation

       4.15.3.3.Threat of forward integration

       4.15.3.4.Buyers volume

   4.15.4.Bargainning power of suppliers

       4.15.4.1.Suppliers concentration

       4.15.4.2.Buyers switching cost to other suppliers

       4.15.4.3.Threat of backward integration

   4.15.5.Bargainning power of suppliers

       4.15.5.1.Industry concentration

       4.15.5.2.Industry growth rate

       4.15.5.3.Product differentiation

   4.15.6.Patent analysis

4.16.Patent quality and strength

4.17.Regulation coverage

4.18.Pricing analysis

4.19.Competitive Metric Space Analysis

Chapter 5. Market Overview

5.1. Drivers

       5.1.1.Rising demand for advanced cancer treatments

       5.1.2.Strong clinical outcomes and regulatory approvals

       5.1.3.Growing investments and collaborations

5.2. Restraints

       5.2.1.High cost of therapy

       5.2.2.Complex manufacturing process

5.3. Opportunities

       5.3.1.Expansion beyond blood cancers

       5.3.2.Technological advancements in manufacturing

       5.3.3.Rising demand in Asia-Pacific

5.4. Threat

       5.4.1.Competition from alternative cancer therapies

       5.4.2.Safety concerns and side effects

Chapter 6. Global CAR-T Cell Therapy Market By Product Type Insights & Trends, Revenue (USD Million)

6.1. Product Type Dynamics & Market Share, 2025-2032

       6.1.1.Yescarta (Axicabtagene Ciloleucel)

       6.1.2.Kymriah (Tisagenlecleucel)

       6.1.3.Breyanzi (Lisocabtagene Maraleucel)

       6.1.4.Abecma (Idecabtagene Vicleucel)

       6.1.5.Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)

       6.1.6.Tecartus (Brexucabtagene Autoleucel)

Chapter 7. Global CAR-T Cell Therapy Market By Target Antigen Type Insights & Trends, Revenue (USD Million)

7.1. Target Antigen Dynamics & Market Share, 2025–2032

       7.1.1.CD19 (Cluster of Differentiation 19)

       7.1.2.BCMA (B-cell Maturation Antigen)

       7.1.3.CD22 (Cluster of Differentiation 22)

       7.1.4.GD2 (Disialoganglioside GD2)

       7.1.5.HER2 (Human Epidermal Growth Factor Receptor 2)

       7.1.6.GPC3 (Glypican-3)

       7.1.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

Chapter 8. Global CAR-T Cell Therapy Market By Disease/Indication Type Insights & Trends, Revenue (USD Million)

8.1. Disease/Indication Dynamics & Market Share, 2025–2032

       8.1.1.Hematologic Malignancies (Blood Cancers)

             8.1.1.1.Lymphoma

                         8.1.1.1.1.Diffuse Large B-cell Lymphoma (DLBCL)

                         8.1.1.1.2.Primary Mediastinal B-cell Lymphoma (PMBCL)

                         8.1.1.1.3.Mantle Cell Lymphoma (MCL)

                         8.1.1.1.4.Follicular Lymphoma (FL)

                         8.1.1.1.5.Other (Non-Hodgkin Lymphomas (NHLs))

             8.1.1.2.Leukemia

                         8.1.1.2.1.Acute Lymphoblastic Leukemia (ALL)

                         8.1.1.2.2.Chronic Lymphocytic Leukemia (CLL)

             8.1.1.3.Multiple Myeloma

                         8.1.1.3.1.B-cell Maturation Antigen (BCMA)

       8.1.2.Solid Tumours

             8.1.2.1.Glioblastoma

             8.1.2.2.Pancreatic Cancer

             8.1.2.3.Ovarian Cancer

             8.1.2.4.Breast Cancer

             8.1.2.5.Lung Cancer

             8.1.2.6.Melanoma

             8.1.2.7.Prostate Cancer

             8.1.2.8.Others (Neuroblastoma Cancer, Colorectal Cancer)

       8.1.3.Other Diseases

             8.1.3.1.Autoimmune Diseases

             8.1.3.2.Infectious Diseases

Chapter 9. Global CAR-T Cell Therapy Market By Manufacturing Method Type Insights & Trends, Revenue (USD Million)

9.1. Manufacturing Method Dynamics & Market Share, 2025–2032

       9.1.1.Point-of-Care Manufacturing

       9.1.2.Centralized manufacturing

       9.1.3.In vivo CAR-T therapy manufacturing

       9.1.4.Off-the-shelf / Ready-to-use therapies

Chapter 10. Global CAR-T Cell Therapy Market By Technology/Vector Type Insights & Trends, Revenue (USD Million)

10.1.Technology/Vector Dynamics & Market Share, 2025–2032

       10.1.1.Viral Vectors

                  10.1.1.1.Lentiviral vectors

                  10.1.1.2.Retroviral vectors

       10.1.2.Non- Viral Vectors

                  10.1.2.1.CRISPR/Cas9 gene editing

                  10.1.2.2.Transposons (Sleeping Beauty, PiggyBac)

                  10.1.2.3.mRNA electroporation

       10.1.3.Armored CAR-T-Cells (enhanced T-cell persistence/activity)

       10.1.4.Safety Switch-Equipped CAR-T Cells

       10.1.5.Dual and multiple antigens targeting CAR-T-cell

Chapter 11. Global CAR-T Cell Therapy Market By Therapy Type Insights & Trends, Revenue (USD Million)

11.1.Therapy Dynamics & Market Share, 2025–2032

       11.1.1.Autologous CAR-T cell therapy

       11.1.2.Allogeneic CAR-T cell therapy

Chapter 12. Global CAR-T Cell Therapy Market By End User Insights & Trends, Revenue (USD Million)

12.1.End Use Dynamics & Market Share, 2025–2032

       12.1.1.Hospitals

       12.1.2.Cancer Treatment Centers

       12.1.3.Contract Development and Manufacturing Organization

       12.1.4.Academic & Research Institutes

       12.1.5.Specialty Clinics

13. Global CAR-T Cell Therapy Market Regional Outlook

       13.1. Global CAR-T Cell Therapy Market Share By Region, 2025–2032

       13.2. North America

                  13.2.1. Market By ProductType, Market Estimates and Forecast, USD Million

                  13.2.2.Yescarta (Axicabtagene Ciloleucel)

                  13.2.3.Kymriah (Tisagenlecleucel)

                  13.2.4.Breyanzi (Lisocabtagene Maraleucel)

                  13.2.5.Abecma (Idecabtagene Vicleucel)

                  13.2.6.Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)

                  13.2.7.Tecartus (Brexucabtagene Autoleucel)

       13.3.Market By Target Antigen, Market Estimates and Forecast, USD Million

                  13.3.1.CD19 (Cluster of Differentiation 19)

                  13.3.2.BCMA (B-cell Maturation Antigen)

                  13.3.3.CD22 (Cluster of Differentiation 22)

                  13.3.4.GD2 (Disialoganglioside GD2)

                  13.3.5.HER2 (Human Epidermal Growth Factor Receptor 2)

                  13.3.6.GPC3 (Glypican-3)

                  13.3.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

       13.4.Market By Disease/Indication Type, Market Estimates and Forecast, USD Million

             13.4.1.Hematologic Malignancies (Blood Cancers)

                        13.4.1.1.Lymphoma

                        13.4.1.1.1.Diffuse Large B-cell Lymphoma (DLBCL)

                        13.4.1.1.2.Primary Mediastinal B-cell Lymphoma (PMBCL)

                        13.4.1.1.3.Mantle Cell Lymphoma (MCL)

                        13.4.1.1.4.Follicular Lymphoma (FL)

                        13.4.1.1.5.Other (Non-Hodgkin Lymphomas (NHLs))

             13.4.1.2.Leukemia

                        13.4.1.2.1.Acute Lymphoblastic Leukemia (ALL)

                        13.4.1.2.2.Chronic Lymphocytic Leukemia (CLL)

             13.4.1.3.Multiple Myeloma

                        13.4.1.3.1.B-cell Maturation Antigen (BCMA)

       13.4.2.Solid Tumours

             13.4.2.1.Glioblastoma

             13.4.2.2.Pancreatic Cancer

             13.4.2.3.Ovarian Cancer

             13.4.2.4.Breast Cancer

             13.4.2.5.Lung Cancer

             13.4.2.6.Melanoma

             13.4.2.7.Prostate Cancer

             13.4.2.8.Others (Neuroblastoma Cancer, Colorectal Cancer)

       13.4.3.Other Diseases

             13.4.3.1.Autoimmune Diseases

             13.4.3.2.Infectious Diseases

       13.5.Market By Manufacturing Method, Market Estimates and Forecast, USD Million

             13.5.1.Point-of-Care Manufacturing

             13.5.2.Centralized manufacturing

             13.5.3.In vivo CAR-T therapy manufacturing

             13.5.4.Off-the-shelf / Ready-to-use therapies

       13.6.Market By Technology/Vector, Market Estimates and Forecast, USD Million

             13.6.1.Viral Vectors

                        13.6.1.1.Lentiviral vectors

                        13.6.1.2.Retroviral vectors

             13.6.2.Non- Viral Vectors

                        13.6.2.1.CRISPR/Cas9 gene editing

                        13.6.2.2.Transposons (Sleeping Beauty, PiggyBac)

                        13.6.2.3.mRNA electroporation

       13.6.3.Armored CAR-T-Cells (enhanced T-cell persistence/activity)

       13.6.4.Safety Switch-Equipped CAR-T Cells

       13.6.5.Dual and multiple antigens targeting CAR-T-cell

       13.7.Market By Therapy Type, Market Estimates and Forecast, USD Million

                        13.7.1.Autologous CAR-T cell therapy

                        13.7.2.Allogeneic CAR-T cell therapy

       13.8.Market By End User, Market Estimates and Forecast, USD Million

                        13.8.1.Hospitals

                        13.8.2.Cancer Treatment Centers

                        13.8.3.Contract Development and Manufacturing Organization

                        13.8.4.Academic & Research Institutes

                        13.8.5.Specialty Clinics

       13.9.Market By Country, Market Estimates and Forecast, USD Million

                        13.9.1.US

                        13.9.2.Canada

                        13.9.3.Mexico

       13.10. Europe

       13.11.Market By ProductType, Market Estimates and Forecast, USD Million

                        13.11.1.Yescarta (Axicabtagene Ciloleucel)

                        13.11.2.Kymriah (Tisagenlecleucel)

                        13.11.3.Breyanzi (Lisocabtagene Maraleucel)

                        13.11.4.Abecma (Idecabtagene Vicleucel)

                        13.11.5.Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)

                        13.11.6.Tecartus (Brexucabtagene Autoleucel)

       13.12.Market By Target Antigen, Market Estimates and Forecast, USD Million

                        13.12.1.CD19 (Cluster of Differentiation 19)

                        13.12.2.BCMA (B-cell Maturation Antigen)

                        13.12.3.CD22 (Cluster of Differentiation 22)

                        13.12.4.GD2 (Disialoganglioside GD2)

                        13.12.5.HER2 (Human Epidermal Growth Factor Receptor 2)

                        13.12.6.GPC3 (Glypican-3)

                        13.12.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

       13.13.Market By Target Antigen, Market Estimates and Forecast, USD Million,

                        13.13.1.CD19 (Cluster of Differentiation 19)

                        13.13.2.BCMA (B-cell Maturation Antigen)

                        13.13.3.CD22 (Cluster of Differentiation 22)

                        13.13.4.GD2 (Disialoganglioside GD2)

                        13.13.5.HER2 (Human Epidermal Growth Factor Receptor 2)

                        13.13.6.GPC3 (Glypican-3)

                        13.13.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

       13.14.Market By Disease/Indication Type, Market Estimates and Forecast, USD Million

             13.14.1.Hematologic Malignancies (Blood Cancers)

                         13.14.1.1.Lymphoma

                                     13.14.1.1.1.Diffuse Large B-cell Lymphoma (DLBCL)

                                     13.14.1.1.2.Primary Mediastinal B-cell Lymphoma (PMBCL)

                                     13.14.1.1.3.Mantle Cell Lymphoma (MCL)

                                     13.14.1.1.4.Follicular Lymphoma (FL)

                                     13.14.1.1.5.Other (Non-Hodgkin Lymphomas (NHLs))

                         13.14.1.2.Leukemia

                                     13.14.1.2.1.Acute Lymphoblastic Leukemia (ALL)

                                     13.14.1.2.2.Chronic Lymphocytic Leukemia (CLL)

                         13.14.1.3.Multiple Myeloma

                                     13.14.1.3.1.B-cell Maturation Antigen (BCMA)

                         13.14.2.Solid Tumours

                                     13.14.2.1.Glioblastoma

                                     13.14.2.2.Pancreatic Cancer

                                     13.14.2.3.Ovarian Cancer

                                     13.14.2.4.Breast Cancer

                                     13.14.2.5.Lung Cancer

                                     13.14.2.6.Melanoma

                                     13.14.2.7.Prostate Cancer

                                     13.14.2.8.Others (Neuroblastoma Cancer, Colorectal Cancer)

                         13.14.3.Other Diseases

                                     13.14.3.1.Autoimmune Diseases

                                     13.14.3.2.Infectious Diseases

                         13.15.Market By Manufacturing Method, Market Estimates and Forecast, USD Million,

                                     13.15.1.Point-of-Care Manufacturing

                                     13.15.2.Centralized manufacturing

                                     13.15.3.In vivo CAR-T therapy manufacturing

                                     13.15.4.Off-the-shelf / Ready-to-use therapies

                         13.16.Market By Technology/Vector Type, Market Estimates and Forecast, USD Million

                                     13.16.1. Viral Vectors

                                              13.16.1.1.Lentiviral vectors

                                              13.16.1.2.Retroviral vectors

                                     13.16.2.Non- Viral Vectors

                                              13.16.2.1.CRISPR/Cas9 gene editing

                                              13.16.2.2.Transposons (Sleeping Beauty, PiggyBac)

                                              13.16.2.3.mRNA electroporation

                                     13.16.3.Armored CAR-T-Cells (enhanced T-cell persistence/activity)

                                     13.16.4.Safety Switch-Equipped CAR-T Cells

                                     13.16.5.Dual and multiple antigens targeting CAR-T-cell

                         13.17.Market By Therapy Type, Market Estimates and Forecast, USD Million

                                     13.17.1.Autologous CAR-T cell therapy

                                     13.17.2.Allogeneic CAR-T cell therapy

                         13.18.Market By End User, Market Estimates and Forecast, USD Million

                                     13.18.1.Hospitals

                                     13.18.2.Cancer Treatment Centers

                                     13.18.3.Contract Development and Manufacturing Organization

                                     13.18.4.Academic & Research Institutes

                                     13.18.5.Specialty Clinics

                         13.19.Market By Country, Market Estimates and Forecast, USD Million

                                     13.19.1.Germany

                                     13.19.2.France

                                     13.19.3.U.K

                                     13.19.4.Italy

                                     13.19.5.Spain

                                     13.19.6.Turkey

                                     13.19.7.Benelux

                                     13.19.8.Russia

                                     13.19.9.Finland

                                     13.19.10.Sweden

                                     13.19.11.Rest Of Europe

                         13.20. Asia-Pacific

                                     13.20.1. Market By ProductType, Market Estimates and Forecast, USD Million

                                     13.20.2.Yescarta (Axicabtagene Ciloleucel)

                                     13.20.3.Kymriah (Tisagenlecleucel)

                                     13.20.4.Breyanzi (Lisocabtagene Maraleucel)

                                     13.20.5.Abecma (Idecabtagene Vicleucel)

                                     13.20.6.Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)

                                     13.20.7.Tecartus (Brexucabtagene Autoleucel)

                         13.21.Market By Target Antigen, Market Estimates and Forecast, USD Million

                                     13.21.1.CD19 (Cluster of Differentiation 19)

                                     13.21.2.BCMA (B-cell Maturation Antigen)

                                     13.21.3.CD22 (Cluster of Differentiation 22)

                                     13.21.4.GD2 (Disialoganglioside GD2)

                                     13.21.5.HER2 (Human Epidermal Growth Factor Receptor 2)

                                     13.21.6.GPC3 (Glypican-3)

                                     13.21.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

       13.22.Market By Disease/Indiaction Type, Market Estimates and Forecast, USD Million,

             13.22.1.Hematologic Malignancies (Blood Cancers)

                         13.22.1.1.Lymphoma

                                     13.22.1.1.1.Diffuse Large B-cell Lymphoma (DLBCL)

                                     13.22.1.1.2.Primary Mediastinal B-cell Lymphoma (PMBCL)

                                     13.22.1.1.3.Mantle Cell Lymphoma (MCL)

                                     13.22.1.1.4.Follicular Lymphoma (FL)

                                     13.22.1.1.5.Other (Non-Hodgkin Lymphomas (NHLs))

                         13.22.1.2.Leukemia

                                     13.22.1.2.1.Acute Lymphoblastic Leukemia (ALL)

                                     13.22.1.2.2.Chronic Lymphocytic Leukemia (CLL)

                         13.22.1.3.Multiple Myeloma

                                     13.22.1.3.1.B-cell Maturation Antigen (BCMA)

                         13.22.2.Solid Tumours

                                    13.22.2.1.Glioblastoma

                                    13.22.2.2.Pancreatic Cancer

                                    13.22.2.3.Ovarian Cancer

                                    13.22.2.4.Breast Cancer

                                    13.22.2.5.Lung Cancer

                                    13.22.2.6.Melanoma

                                    13.22.2.7.Prostate Cancer

                                    13.22.2.8.Others (Neuroblastoma Cancer, Colorectal Cancer)

                         13.22.3.Other Diseases

                                     13.22.3.1.Autoimmune Diseases

                                     13.22.3.2.Infectious Diseases

                         13.23.Market By Manufacturing method, Market Estimates and Forecast, USD Million

                                     13.23.1.Point-of-Care Manufacturing

                                     13.23.2.Centralized manufacturing

                                     13.23.3.In vivo CAR-T therapy manufacturing

                                     13.23.4.Off-the-shelf / Ready-to-use therapies

                         13.24.Market By Technology/Vector, Market Estimates and Forecast, USD Million

                                     13.24.1.Viral Vectors

                                              13.24.1.1.Lentiviral vectors

                                              13.24.1.2.Retroviral vectors

                                     13.24.2.Non- Viral Vectors

                                              13.24.2.1.CRISPR/Cas9 gene editing

                                              13.24.2.2.Transposons (Sleeping Beauty, PiggyBac)

                                              13.24.2.3.mRNA electroporation

                                     13.24.3.Armored CAR-T-Cells (enhanced T-cell persistence/activity)

                                     13.24.4.Safety Switch-Equipped CAR-T Cells

                                     13.24.5.Dual and multiple antigens targeting CAR-T-cell

                         13.25.Market By Therapy Type, Market Estimates and Forecast, USD Million

                                     13.25.1.Autologous CAR-T cell therapy

                                     13.25.2.Allogeneic CAR-T cell therapy

                         13.26.Market By End User, Market Estimates and Forecast, USD Million

                                     13.26.1.Hospitals

                                     13.26.2.Cancer Treatment Centers

                                     13.26.3.Contract Development and Manufacturing Organization

                                     13.26.4.Academic & Research Institutes

                                     13.26.5.Specialty Clinics

                         13.27.Market By Country, Market Estimates and Forecast, USD Million

                                     13.27.1.1.China

                                     13.27.1.2.India

                                     13.27.1.3.Japan

                                     13.27.1.4.South Korea

                                     13.27.1.5.Indonesia

                                     13.27.1.6.Thailand

                                     13.27.1.7.Vietnam

                                     13.27.1.8.Australia

                                     13.27.1.9.New Zeland

                                     13.27.1.10.Rest of APAC

Chapter 14. Latin America

       14.1.1. Market By Product Type, Market Estimates and Forecast, USD Million

                   14.1.2.Yescarta (Axicabtagene Ciloleucel)

                   14.1.3.Kymriah (Tisagenlecleucel)

                   14.1.4.Breyanzi (Lisocabtagene Maraleucel)

                   14.1.5.Abecma (Idecabtagene Vicleucel)

                   14.1.6.Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)

                   14.1.7.Tecartus (Brexucabtagene Autoleucel)

       14.2.Market By Target Antigen, Market Estimates and Forecast, USD Million

                   14.2.1.CD19 (Cluster of Differentiation 19)

                   14.2.2.BCMA (B-cell Maturation Antigen)

                   14.2.3.CD22 (Cluster of Differentiation 22)

                   14.2.4.GD2 (Disialoganglioside GD2)

                   14.2.5.HER2 (Human Epidermal Growth Factor Receptor 2)

                   14.2.6.GPC3 (Glypican-3)

                   14.2.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

       14.3.Market By Disease/Indication Type, Market Estimates and Forecast, USD Million

         14.4. Disease/Indication Dynamics & Market Share, 2025–2032

             14.4.1.Hematologic Malignancies (Blood Cancers)

                     14.4.1.1.Lymphoma

                        14.4.1.1.1.Diffuse Large B-cell Lymphoma (DLBCL)

                        14.4.1.1.2.Primary Mediastinal B-cell Lymphoma (PMBCL)

                        14.4.1.1.3.Mantle Cell Lymphoma (MCL)

                        14.4.1.1.4.Follicular Lymphoma (FL)

                        14.4.1.1.5.Other (Non-Hodgkin Lymphomas (NHLs))

                     14.4.1.2.Leukemia

                        14.4.1.2.1.Acute Lymphoblastic Leukemia (ALL)

                        14.4.1.2.2.Chronic Lymphocytic Leukemia (CLL)

                     14.4.1.3.Multiple Myeloma

                        14.4.1.3.1.B-cell Maturation Antigen (BCMA)

                     14.4.2.Solid Tumours

                        14.4.2.1.Glioblastoma

                        14.4.2.2.Pancreatic Cancer

                        14.4.2.3.Ovarian Cancer

                        14.4.2.4.Breast Cancer

                        14.4.2.5.Lung Cancer

                        14.4.2.6.Melanoma

                        14.4.2.7.Prostate Cancer

                        14.4.2.8.Others (Neuroblastoma Cancer, Colorectal Cancer)

                     14.4.3.Other Diseases

                        14.4.3.1.Autoimmune Diseases

                        14.4.3.2.Infectious Diseases

       14.5.Market By Manufacturing method, Market Estimates and Forecast, USD Million

         14.5.1.Point-of-Care Manufacturing

         14.5.2.Centralized manufacturing

         14.5.3.In vivo CAR-T therapy manufacturing

         14.5.4.Off-the-shelf / Ready-to-use therapies

       14.6.Market By Technology/Vector, Market Estimates and Forecast, USD Million

         14.6.1.Viral Vectors

                 14.6.1.1.Lentiviral vectors

                 14.6.1.2.Retroviral vectors

         14.6.2.Non- Viral Vectors

                 14.6.2.1.CRISPR/Cas9 gene editing

                 14.6.2.2.Transposons (Sleeping Beauty, PiggyBac)

                 14.6.2.3.mRNA electroporation

         14.6.3.Armored CAR-T-Cells (enhanced T-cell persistence/activity)

         14.6.4.Safety Switch-Equipped CAR-T Cells

         14.6.5.Dual and multiple antigens targeting CAR-T-cell

       14.7.Market By End User, Market Estimates and Forecast, USD Million

         14.7.1. Hospitals

         14.7.2.Cancer Treatment Centers

         14.7.3.Contract Development and Manufacturing Organization

         14.7.4.Academic & Research Institutes

         14.7.5.Specialty Clinics

       14.8.Market By Therapy Type, Market Estimates and Forecast, USD Million

         14.8.1.Autologous CAR-T cell therapy

         14.8.2.Allogeneic CAR-T cell therapy

       14.9.Market By Country, Market Estimates and Forecast, USD Million

         14.9.1.Brazil

         14.9.2.Rest of LATAM

14.10.Middle East & Africa

       14.10.1. Market By ProductType, Market Estimates and Forecast, USD Million

                    14.10.2.Yescarta (Axicabtagene Ciloleucel)

                    14.10.3.Kymriah (Tisagenlecleucel)

                    14.10.4.Breyanzi (Lisocabtagene Maraleucel)

                   14.10.5.Abecma (Idecabtagene Vicleucel)

                    14.10.6.Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)

                    14.10.7.Tecartus (Brexucabtagene Autoleucel)

       14.11.Market By Target Antigen, Market Estimates and Forecast, USD Million

                    14.11.1.CD19 (Cluster of Differentiation 19)

                    14.11.2.BCMA (B-cell Maturation Antigen)

                    14.11.3.CD22 (Cluster of Differentiation 22)

                    14.11.4.GD2 (Disialoganglioside GD2)

                    14.11.5.HER2 (Human Epidermal Growth Factor Receptor 2)

                    14.11.6.GPC3 (Glypican-3)

                    14.11.7.Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)

       14.12.Market By Disease/Indication, Market Estimates and Forecast, USD Million

                    14.12.1.Hematologic Malignancies (Blood Cancers)

                         14.12.1.1.Lymphoma

                                     14.12.1.1.1.Diffuse Large B-cell Lymphoma (DLBCL)

                                     14.12.1.1.2.Primary Mediastinal B-cell Lymphoma (PMBCL)

                                     14.12.1.1.3.Mantle Cell Lymphoma (MCL)

                                     14.12.1.1.4.Follicular Lymphoma (FL)

                                     14.12.1.1.5.Other (Non-Hodgkin Lymphomas (NHLs))

                         14.12.1.2.Leukemia

                                     14.12.1.2.1.Acute Lymphoblastic Leukemia (ALL)

                                     14.12.1.2.2.Chronic Lymphocytic Leukemia (CLL)

                         14.12.1.3.Multiple Myeloma

                                     14.12.1.3.1.B-cell Maturation Antigen (BCMA)

                         14.12.2.Solid Tumours

                                     14.12.2.1.Glioblastoma

                                     14.12.2.2.Pancreatic Cancer

                                     14.12.2.3.Ovarian Cancer

                                     14.12.2.4.Breast Cancer

                                     14.12.2.5.Lung Cancer

                                     14.12.2.6.Melanoma

                                     14.12.2.7.Prostate Cancer

                                     14.12.2.8.Others (Neuroblastoma Cancer, Colorectal Cancer)

                         14.12.3.Other Diseases

                                   14.12.3.1.Autoimmune Diseases

                                   14.12.3.2.Infectious Diseases

       14.13.Market By Manufacturing method, Market Estimates and Forecast, USD Million

                                   14.13.1.Point-of-Care Manufacturing

                                   14.13.2.Centralized manufacturing

                                   14.13.3.In vivo CAR-T therapy manufacturing

                                   14.13.4.Off-the-shelf / Ready-to-use therapies

       14.14.Market By Technology/Vector, Market Estimates and Forecast, USD Million

                    14.14.1.Viral Vectors

                                     14.14.1.1.Lentiviral vectors

                                     14.14.1.2.Retroviral vectors

                    14.14.2.Non- Viral Vectors

                                     14.14.2.1.CRISPR/Cas9 gene editing

                                     14.14.2.2.Transposons (Sleeping Beauty, PiggyBac)

                                     14.14.2.3.mRNA electroporation

       14.14.3.Armored CAR-T-Cells (enhanced T-cell persistence/activity)

       14.14.4.Safety Switch-Equipped CAR-T Cells

       14.14.5.Dual and multiple antigens targeting CAR-T-cell

       14.15.Market By Therapy Type, Market Estimates and Forecast, USD Million

                    14.15.1.Autologous CAR-T cell therapy

                    14.15.2.Allogeneic CAR-T cell therapy

       14.16.Market By End User, Market Estimates and Forecast, USD Million

                    14.16.1.Hospitals

                    14.16.2.Cancer Treatment Centers

                    14.16.3.Contract Development and Manufacturing Organization

                    14.16.4.Academic & Research Institutes

                    14.16.5.Specialty Clinics

       14.17.Market By Country, Market Estimates and Forecast, USD Million

                    14.17.1.Saudi Arabia

                    14.17.2.UAE

                    14.17.3.South Africa

                    14.17.4.Turkey

                    14.17.5.Rest of MEA

Chapter  15. Competitive Landscape

15.1. Market Revenue Share By Manufacturers

15.2. Mergers & Acquisitions

15.3. Competitor’s Positioning

15.4. Strategy Benchmarking

15.5. Vendor Landscape

            15.5.1.Distributors

                    15.5.1.1.North America

                    15.5.1.2.Europe

                    15.5.1.3.Asia Pacific

                    15.5.1.4.Middle East & Africa

                    15.5.1.5.Latin America

            15.5.2.Others

Chapter 16. Company Profiles

            16.1.Bluebird Bio

                    16.1.1.Company Overview

                    16.1.2.Product & Service Offerings

                    16.1.3.Strategic Initiatives

                    16.1.4.Financials

                    16.1.5.Research Insights

            16.2.Celgene Corporation

                    16.2.1.Company Overview

                    16.2.2.Product & Service Offerings

                    16.2.3.Strategic Initiatives

                    16.2.4.Financials

                    16.2.5.Research Insights

            16.3.Gilead Sciences

                   16.3.1.Company Overview

                   16.3.2.Product & Service Offerings

                   16.3.3.Strategic Initiatives

                   16.3.4.Financials

                   16.3.5.Research Insights

            16.4.Cellectis

                  16.4.1.Company Overview

                  16.4.2.Product & Service Offerings

                  16.4.3.Strategic Initiatives

                  16.4.4.Financials

                  16.4.5.Research Insights

            16.5.Servier Laboratories

                  16.5.1.Company Overview

                  16.5.2.Product & Service Offerings

                  16.5.3.Strategic Initiatives

                  16.5.4.Financials

                  16.5.5.Research Insights

            16.6.Pfizer Inc.

                  16.6.1.Company Overview

                  16.6.2.Product & Service Offerings

                  16.6.3.Strategic Initiatives

                  16.6.4.Financials

                  16.6.5.Research Insights

            16.7.Merck

                  16.7.1.Company Overview

                  16.7.2.Product & Service Offerings

                  16.7.3.Strategic Initiatives

                  16.7.4.Financials

                  16.7.5.Conclusion

            16.8.Amgen

                  16.8.1.Company Overview

                  16.8.2.Product & Service Offerings

                  16.8.3.Strategic Initiatives

                  16.8.4.Financials

                  16.8.5.Conclusion

            16.9.Intellia Therapeutics

                  16.9.1.Company Overview

                  16.9.2.Product & Service Offerings

                  16.9.3.Strategic Initiatives

                  16.9.4.Financials

                  16.9.5.Conclusion

            16.10.Novartis

                  16.10.1.Company Overview

                  16.10.2.Product & Service Offerings

                  16.10.3.Strategic Initiatives

                  16.10.4.Financials

                  16.10.5.Conclusion

            16.11.Caribou Biosciences

                  16.11.1.Company Overview

                  16.11.2.Product & Service Offerings

                  16.11.3.Strategic Initiatives

                  16.11.4.Financials

                  16.11.5.Conclusion

            16.12.Celyad

                  16.12.1.Company Overview

                  16.12.2.Product & Service Offerings

                  16.12.3.Strategic Initiatives

                  16.12.4.Financials

                  16.12.5.Conclusion

            16.13.Bellicum Pharmaceuticals, Inc.

                  16.13.1.Company Overview

                  16.13.2.Product & Service Offerings

                  16.13.3.Strategic Initiatives

                  16.13.4.Financials

                  16.13.5.Conclusion

            16.14.Noile-Immune Biotech

                  16.14.1.Company Overview

                  16.14.2.Product & Service Offerings

                  16.14.3.Strategic Initiatives

                  16.14.4.Financials

                  16.14.5.Conclusion

            16.15.Nanjing Legend Biotechnology Co., Ltd.

                  16.15.1.Company Overview

                  16.15.2.Product & Service Offerings

                  16.15.3.Strategic Initiatives

                  16.15.4.Financials

                  16.15.5.Conclusion

            16.16.Johnson & Johnson

                  16.16.1.Company Overview

                  16.16.2.Product & Service Offerings

                  16.16.3.Strategic Initiatives

                  16.16.4.Financials

                  16.16.5.Conclusion

            16.17.Sangamo Therapeutics, Inc.

                  16.17.1.Company Overview

                  16.17.2.Product & Service Offerings

                  16.17.3.Strategic Initiatives

                  16.17.4.Financials

                  16.17.5.Conclusion

            16.18.Autolus Therapeutics

                  16.18.1.Company Overview

                  16.18.2.Product & Service Offerings

                  16.18.3.Strategic Initiatives

                  16.18.4.Financials

                  16.18.5.Conclusion

            16.19.Poseida Therapeutics

                  16.19.1.Company Overview

                  16.19.2.Product & Service Offerings

                  16.19.3.Strategic Initiatives

                  16.19.4.Financials

                  16.19.5.Conclusion

           16.20.Allogene Therapeutics

                  16.20.1.Company Overview

                  16.20.2.Product & Service Offerings

                  16.20.3.Strategic Initiatives

                  16.20.4.Financials

                  16.20.5.Conclusion

           16.21.Arcellx.

                 16.21.1.Company Overview

                 16.21.2.Product & Service Offerings

                 16.21.3.Strategic Initiatives

                 16.21.4.Financials

                 16.21.5.Conclusion

           16.22.JW Therapeutics

                 16.22.1.Company Overview

                 16.22.2.Product & Service Offerings

                 16.22.3.Strategic Initiatives

                 16.22.4.Financials

                 16.22.5.Conclusion

           16.23.Gracell Biotechnologies

                16.23.1.Company Overview

                16.23.2.Product & Service Offerings

                16.23.3.Strategic Initiatives

                16.23.4.Financials

                16.23.5.Conclusion

           16.24.Mustang Bio.

                16.24.1.Company Overview

                16.24.2.Product & Service Offerings

                16.24.3.Strategic Initiatives

                16.24.4.Financials

                16.24.5.Conclusion

           16.25.Cellular Biomedicine Group

                16.25.1.Company Overview

                16.25.2.Product & Service Offerings

                16.25.3.Strategic Initiatives

                16.25.4.Financials

                16.25.5.Conclusion

Segments covered in report

For the purpose of this report, Advantia Business Consulting LLP. has segmented global CAR-T cell therapy market on the basis of Product Type, By Target Antigen Type, By Disease/Indication Type, By Manufacturing Method, By Technology/Vector Type, By Therapy Type, By End User and By Region.

  • Global Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Global Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Global Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Global Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing 
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Global Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Global Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Global Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • North America
  • Dual and multiple antigens targeting CAR T-cell
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • North America Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • North America Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • North America Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • North America Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • North America Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • North America Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • U.S.
  • U.S. Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • U.S. Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • U.S. Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • U.S. Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • U.S. Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • U.S. Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • U.S. Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Canada
  • Canada Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Canada Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Canada Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Canada Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Canada Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Canada Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Canada Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Mexico
  • Mexico Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Mexico Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Mexico Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Mexico Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Mexico Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Mexico Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Mexico Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)

Europe

  • Europe Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Europe Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Europe Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Europe Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Europe Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Europe Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Europe Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Germany
  • Germany Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Germany Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Germany Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Germany Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Germany Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Germany Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Germany Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • France
  • France Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • France Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • France Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • France Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • France Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • France Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • France Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • U.K.
  • U.K. Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • U.K. Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • U.K. Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • U.K. Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • U.K. Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • U.K. Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • U.K. Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Italy
  • Italy Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Italy Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Italy Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Italy Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Italy Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Italy Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Italy Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Spain
  • Spain Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Spain Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Spain Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Spain Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Spain Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Spain Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Spain Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Benelux
  • Benelux Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Benelux Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Benelux Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Benelux Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Benelux Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Benelux Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Benelux Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Russia
  • Russia Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Russia Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
    • Russia Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Russia Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Russia Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Russia Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Russia Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Finland
  • Finland Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Finland Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
    • Finland Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Finland Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Finland Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Finland Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Finland Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Sweden
  • Sweden Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Sweden Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Sweden Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Sweden Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Sweden Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Sweden Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Sweden Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Rest of Europe
  • Rest of Europe Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Rest of Europe Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Rest of Europe Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Rest of Europe Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Rest of Europe Type Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Rest of Europe Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Asia Pacific
  • Asia Pacific Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Asia Pacific Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Asia Pacific Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Asia Pacific Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Asia Pacific Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Asia Pacific Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Asia Pacific Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • China
  • China Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • China Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • China Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • China Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • China Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • China Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • China Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • India
  • India Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • India Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • India Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • India Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • India Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • India Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • India Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Japan
  • Japan Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Japan Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Japan Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Japan Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Japan Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Japan Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Japan Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • South Korea
  • South Korea Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • South Korea Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • South Korea Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • South Korea Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • South Korea Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • South Korea Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • South Korea Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Indonesia
  • Indonesia Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Indonesia Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Indonesia Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Indonesia Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Indonesia Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Indonesia Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Indonesia Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)

Thailand

  • Thailand Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Thailand Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Thailand Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Thailand Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Thailand Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Thailand Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Thailand Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)

Vietnam

  • Vietnam Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Vietnam Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Vietnam Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Vietnam Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Vietnam Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Vietnam Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Vietnam Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Australia
  • Australia Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Australia Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Australia Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Australia Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Australia Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Australia Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Australia Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • New Zealand
  • New Zealand Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • New Zealand Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • New Zealand Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • New Zealand Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • New Zealand Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • New Zealand Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • New Zealand Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Rest of APAC
  • Rest of APAC Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Rest of APAC Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Rest of APAC Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Rest of APAC Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Rest of APAC Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Rest of APAC Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Rest of APAC Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Latin America
  • Latin America Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Latin America Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Latin America Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Latin America Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Latin America Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Latin America Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Latin America Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Brazil
  • Brazil Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Brazil Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Brazil Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Brazil Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Brazil Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Brazil Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Brazil Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Rest of LATAM
  • Rest of LATAM Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Rest of LATAM Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Rest of LATAM Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Rest of LATAM Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Rest of LATAM Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Rest of LATAM Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Rest of LATAM Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Middle East & Africa
  • Middle East & Africa Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Middle East & Africa Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Middle East & Africa Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Middle East & Africa Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Middle East & Africa Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Middle East & Africa Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Middle East & Africa Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)

Saudi Arabia

  • Saudi Arabia Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Saudi Arabia Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Saudi Arabia Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Saudi Arabia Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Saudi Arabia Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Saudi Arabia Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Saudi Arabia Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • UAE
  • UAE Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • UAE Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • UAE Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • UAE Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • UAE Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • UAE Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • UAE Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • South Africa
  • South Africa Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • South Africa Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • South Africa Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleuce
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • South Africa Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • South Africa Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • South Africa Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • South Africa Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Rest of MEA
  • Rest of MEA Type Product Outlook (Revenue, USD Million; 2025-2032)
    • Yescarta (Axicabtagene Ciloleucel)
    • Kymriah (Tisagenlecleucel)
    • Breyanzi (Lisocabtagene Maraleucel)
    • Abecma (Idecabtagene Vicleucel)
    • Carvykti (Ciltacabtagene Autoleucel / Cilta-cel)
    • Tecartus (Brexucabtagene Autoleucel)
  • Rest of MEA Type Target Antigen Outlook (Revenue, USD Million; 2025-2032)
    • CD19 (Cluster of Differentiation 19)
    • BCMA (B-cell Maturation Antigen)
    • CD22 (Cluster of Differentiation 22)
    • GD2 (Disialoganglioside GD2)
    • HER2 (Human Epidermal Growth Factor Receptor 2)
    • GPC3 (Glypican-3)
    • Others (EGFRvIII, CD7(Cluster of Differentiation 7), CD123(Cluster of Differentiation 123), mesothelin)
  • Rest of MEA Type Disease/Indication Outlook (Revenue, USD Million; 2025-2032)
    • Hematologic Malignancies (Blood Cancers)
      1. Lymphoma
        • Diffuse Large B-cell Lymphoma (DLBCL)
        • Primary Mediastinal B-cell Lymphoma (PMBCL)
        • Mantle Cell Lymphoma (MCL)
        • Follicular Lymphoma (FL)
        • Other (Non-Hodgkin Lymphomas (NHLs)
      1. Leukemia
        • Acute Lymphoblastic Leukemia (ALL)
        • Chronic Lymphocytic Leukemia (CLL)
      1. Multiple Myeloma
        • B-cell Maturation Antigen (BCMA)
  • Solid Tumours
    • Glioblastoma
    • Pancreatic Cancer
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Melanoma
    • Prostate Cancer
    • Others (Neuroblastoma Cancer, Colorectal Cancer)
  • Other Diseases
    • Autoimmune Diseases
    • Infectious Diseases
  • Rest of MEA Type Manufacturing Method Outlook (Revenue, USD Million; 2025-2032)
    • Point-of-Care Manufacturing
    • Centralized manufacturing
    • In-vivo CAR T therapy manufacturing
    • Off-the-shelf / Ready-to-use therapies
  • Rest of MEA Technology/Vector Outlook (Revenue, USD Million; 2025-2032)
    • Viral Vectors
        • Lentiviral vectors)
        • Retroviral vectors
    • Non- Viral Vectors
        • CRISPR/Cas9 gene editing
        • Transposons (Sleeping Beauty, PiggyBac)
        • mRNA electroporation
    • Armored CAR T-Cells (enhanced T-cell persistence/activity)
    •  Safety Switch-Equipped CAR T Cells
    • Dual and multiple antigens targeting CAR T-cell
  • Rest of MEA Type Therapy Outlook (Revenue, USD Million; 2025-2032)
    • Autologous CAR-T cell therapy
    • Allogeneic CAR-T cell therapy
  • Rest of MEA Type End User Outlook (Revenue, USD Million; 2025-2032)
    • Hospitals
    • Cancer Treatment Centers
    • Other (Academic & Research Institutes, Speciality Clinics)
  • Some Key Questions the Report Will Answer
  • What is the expected revenue Compound Annual Growth Rate (CAGR) of the global CAR-T cell therapy market over the forecast period (2025–2032)?
    • The global CAR-T cell therapy market revenue is expected to register a Compound Annual Growth Rate (CAGR) of 38.41% during the forecast period. 
  • What was the size of the global CAR-T cell therapy market in 2025?
    • The global CAR-T cell therapy market size was USD 7,459.42 Million in 2025.
  • Which factors are expected to drive the global CAR-T cell therapy market growth?
    • The growth of the global CAR-T cell therapy market is driven by rising cancer prevalence, growing demand for personalized and targeted therapies, and rapid advancements in genetic engineering and immunotherapy technologies. Expanding clinical trials and strong pipeline development, along with increasing regulatory approvals, are accelerating adoption across hematologic and solid tumors. Moreover, strategic collaborations, mergers and acquisitions, supportive reimbursement policies, rising healthcare spending, and increasing awareness of innovative cell-based treatments are further boosting market expansion worldwide.
  • Which was the leading segment in the global CAR-T cell therapy market in terms of product type in 2025?
    • Yescarta (Axicabtagene Ciloleucel) segment was leading in the global CAR-T cell therapy market on the basis of type in 2025.
  • What are some restraints for revenue growth of the global CAR-T cell therapy market?
    • Revenue growth of the global CAR-T cell therapy market is restrained by the high cost of treatment, which limits patient accessibility, along with complex and time-consuming manufacturing processes that challenge scalability. Stringent regulatory requirements, safety risks such as cytokine release syndrome and neurotoxicity, and limited efficacy in solid tumors further hinder adoption. In addition, reimbursement hurdles and logistical challenges in cell collection, processing, and delivery continue to pose significant barriers to widespread market expansion.